koto_feja/E+ via Getty Images
Summit Therapeutics (NASDAQ:SMMT) announced on Friday that its lead asset, ivonescimab, developed with its Chinese partner Akeso (OTCPK:AKESF), reached the main goal as part of a combination regimen in lung cancer.
Citing topline data from its Phase 3 HARMONi trial, Summit (NASDAQ: